Skyrizi (risankizumab-rzaa)

Manufacturer:

AbbVie

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

Manufacturer Website

phone:

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
treatment of active psoriatic arthritis in adults
treatment of moderately-to-severely active Crohn’s disease in adults
treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease
Plaque Psoriasis
Psoriatic Arthritis
Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology